Saturday, November 15, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Lanxess Stock: Drastic Cuts Amid Market Turmoil

Robert Sasse by Robert Sasse
August 14, 2025
in Stocks
0
Lanxess Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Lanxess, the Cologne-based specialty chemicals firm, has slashed its 2025 earnings forecast due to worsening economic conditions, now projecting an operating profit of €520–580 million, down from €600–650 million. The company cited persistent U.S. tariff disputes and broader market uncertainty as key pressures. Cost-cutting measures include early closures of facilities in Krefeld-Uerdingen (60 jobs lost) and Widnes, UK (70 jobs affected), with expected annual savings of €50 million by late 2027. Q2 results underscored the challenges: revenue fell 13% to €1.47 billion, with agrochemicals and construction sectors hit hardest. Operating profit dropped 17% to €150 million, while net losses widened to €45 million.

Investor Confidence Erodes

The bleak outlook sparked a 3% stock decline to €23.60, extending a 20% slide since May. Analysts noted the forecast cut was steeper than anticipated, with one firm maintaining an "underperform" rating and a €21 target. Management warned of no near-term recovery, compounded by supply chain disruptions costing an additional €10 million. Lanxess joins a growing list of chemical firms downgrading expectations amid global economic headwinds.

Ad

Lanxess Stock: Buy or Sell?! New Lanxess Analysis from November 15 delivers the answer:

The latest Lanxess figures speak for themselves: Urgent action needed for Lanxess investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 15.

Lanxess: Buy or sell? Read more here...

Tags: Lanxess
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Royal Gold Stock
Stocks

Royal Gold Shares Surge to Record High on Acquisition Momentum

September 29, 2025
Unitedhealth Stock
Stocks

UnitedHealth Shares Present Conflicting Outlook for Investors

September 29, 2025
ASML Stock
Stocks

ASML Forges Strategic AI Alliance to Bolster Semiconductor Dominance

September 29, 2025
Next Post
Lenovo Stock

Lenovo Stock: Record Profits, Sharp Decline

JDC Stock

JDC Stock: Stellar Growth Defies Market Challenges

Bilfinger Stock

Bilfinger Stock: Strong Growth Amid Investor Caution

Recommended

Technology Blockchain Markets and money

Analyst Ratings and Price Targets for KLA NASDAQ KLAC

2 years ago
BigBearai Holdings Stock

BigBear.ai Stock: Can Government Contracts Offset Financial Headwinds?

1 month ago
Emerson Electric Stock

Emerson Electric Positions Itself for Lithium-Driven Growth

2 days ago
Alibaba Stock

Alibaba Shares Face Divergent Analyst Views Amid Strategic AI Partnership

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Chip Sector Showdown: AMD’s AI Surge Versus Intel’s Turnaround Bid

Cloudflare Positions for AI Leadership with Strategic Data Initiative

Marvell Technology Shares Face Mounting Pressure

Vertex’s Billion-Dollar Bet on Alpine Immune Sciences: A Strategic Analysis

WiMi Unveils Quantum AI Breakthrough for Holographic Imaging

iSun’s Final Chapter: Liquidation Wipes Out Shareholder Value

Trending

Tesla Stock
Analysis

Tesla’s Strategic Pivot: Supply Chain Overhaul Amid Executive Departures

by Robert Sasse
November 15, 2025
0

Tesla has initiated one of its most significant operational shifts by instructing suppliers to eliminate all China-manufactured...

Phathom Pharmaceuticals Stock

Phathom Pharmaceuticals Stock Surges on Strong Quarterly Performance

November 15, 2025
Verve Therapeutics Stock

Verve Therapeutics Acquisition Marks New Chapter in Gene Editing

November 15, 2025
Intel Stock

Chip Sector Showdown: AMD’s AI Surge Versus Intel’s Turnaround Bid

November 15, 2025
Cloudflare Stock

Cloudflare Positions for AI Leadership with Strategic Data Initiative

November 15, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Tesla’s Strategic Pivot: Supply Chain Overhaul Amid Executive Departures
  • Phathom Pharmaceuticals Stock Surges on Strong Quarterly Performance
  • Verve Therapeutics Acquisition Marks New Chapter in Gene Editing

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com